$24.58
+3.9%Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Strong working capital position provides significant operational flexibility and financial cushion.
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
ELAN โข NYSE
| Elanco Animal Health Incorporated Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||
CURRENT ASSETS | ||||||||||
545M | 468M | 352M | 345M | 638M | 495M | 334M | 474.8M | 323.4M | 258.8M | |
545M | 468M | 352M | 345M | 638M | 495M | 334M | 474.8M | 323.4M | 258.8M | |
940M | 886M | 1B | 1B | 1B | 1.1B | 889.9M | 709.4M | 601.9M | 630.7M | |
940M | 805M | 842M | 797M | 833M | 872M | 816.9M | 651.8M | 567.4M | 585M | |
0.0 | 81M | 168M | 205M | 195M | 205M | 73M | 57.6M | 34.5M | 45.7M | |
1.7B | 1.6B | 1.7B | 1.5B | 1.4B | 1.6B | 1.1B | 1B | 1.1B | 875.6M | |
0.0 | 0.0 | 0.0 | 0.0 | 237M | 256M | 87.4M | 113.9M | 136.1M | 182.3M | |
236M | 287M | 310M | 394M | 0.0 | 11M | 11.1M | 202.7M | 0.0 | 0.0 | |
3.5B | 3.2B | 3.4B | 3.3B | 3.3B | 3.4B | 2.4B | 2.5B | 2.1B | 1.9B | |
NON-CURRENT ASSETS | ||||||||||
1.4B | 993M | 1B | 999M | 1.1B | 1.3B | 955.3M | 922.4M | 920.3M | 741.8M | |
4.8B | 4.4B | 5.1B | 6B | 6.2B | 6.2B | 3B | 3B | 3B | 2.6B | |
3.4B | 3.7B | 4.5B | 4.8B | 5.6B | 6.4B | 2.5B | 2.5B | 2.7B | 2.6B | |
8.2B | 8.1B | 9.6B | 10.8B | 11.8B | 12.6B | 5.5B | 5.4B | 5.6B | 5.2B | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 15.3M | 12.3M | 9M | |
304M | 311M | 341M | 378M | 390M | 348M | 185M | 103.1M | 242M | 204M | |
9.9B | 9.4B | 11B | 12.2B | 13.2B | 14.3B | 6.6B | 6.5B | 6.8B | 6.2B | |
13.4B | 12.6B | 14.4B | 15.5B | 16.5B | 17.7B | 9B | 9B | 8.9B | 8.1B | |
LIABILITIES | ||||||||||
CURRENT LIABILITIES | ||||||||||
368M | 296M | 270M | 390M | 416M | 501M | 239M | 205.2M | 208.6M | 228.2M | |
368M | 296M | 270M | 390M | 416M | 501M | 222.6M | 205.2M | 203.8M | 228.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.4M | 0.0 | 4.8M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 254.8M | 83.2M | |
74M | 44M | 38M | 388M | 294M | 555M | 24.5M | 29M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.8M | 7.5M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 367.6M | 0.0 | 0.0 | |
1.2B | 975M | 933M | 924M | 937M | 1B | 555M | 736.5M | 169.2M | 307.5M | |
1.6B | 1.3B | 1.2B | 1.7B | 1.6B | 2.1B | 818.5M | 970.7M | 632.6M | 618.9M | |
NON-CURRENT LIABILITIES | ||||||||||
3.9B | 4.3B | 5.7B | 5.4B | 6B | 5.6B | 2.3B | 2.4B | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 109.1M | 0.0 | 0.0 | |
0.0 | 449M | 567M | 662M | 765M | 900M | 100.8M | 114.6M | 251.9M | 227.5M | |
1.3B | 477M | 595M | 390M | 533M | 668M | 189.1M | 230.6M | 265M | 225.4M | |
5.2B | 5.2B | 6.9B | 6.5B | 7.3B | 7.1B | 2.6B | 2.8B | 516.9M | 452.9M | |
6.8B | 6.5B | 8.1B | 8.2B | 9B | 9.2B | 3.4B | 3.8B | 1.1B | 1.1B | |
SHAREHOLDERS' EQUITY | ||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8B | 7.5B | |
0.0 | 8.8B | 8.8B | 8.7B | 8.7B | 8.7B | 5.6B | 5.4B | 0.0 | 0.0 | |
-2.2B | -2B | -2.3B | -1.1B | -979M | -477M | 84.3M | 16.4M | 0.0 | 0.0 | |
-141M | -771M | -266M | -392M | -209M | 303M | -173.7M | -222.2M | -256.6M | -456.9M | |
8.9B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.5M | 0.0 | |
6.5B | 6.1B | 6.2B | 7.3B | 7.5B | 8.5B | 5.5B | 5.2B | 7.8B | 7B | |
6.5B | 6.1B | 6.2B | 7.3B | 7.5B | 8.5B | 5.5B | 5.2B | 7.8B | 7B | |
SUMMARY | ||||||||||
13.4B | 12.6B | 14.4B | 15.5B | 16.5B | 17.7B | 9B | 9B | 8.9B | 8.1B | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 15.3M | 12.3M | 9M | |
4B | 4.3B | 5.8B | 5.8B | 6.3B | 6.1B | 2.4B | 2.5B | 0.0 | 0.0 | |
3.5B | 3.9B | 5.4B | 5.5B | 5.7B | 5.6B | 2B | 2B | -323.4M | -258.8M | |
496,863,473 | 496,863,473 | 496,863,473 | 496,863,473 | 496,863,473 | 496,863,473 | 496,863,473 | 496,863,473 | 496,863,473 | 496,863,473 |
ELAN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 27, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 08, 2026 | December 31, 2025 | 2025 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 09, 2025 | December 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 |
Continue your ELAN research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.